TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A USC Schaeffer Center model estimates that donanemab treatment could generate $104,900 in lifetime societal value per person when begun at the timing modeled in a clinical trial. Starting two years earlier raised the estimate by 32%, to $138,300, though the analysis does not subtract drug, screening or monitoring costs and depends on uncertain assumptions about how long treatment benefits last.
Researchers at the USC Schaeffer Center for Health Policy & Economics estimate that starting the Alzheimer’s drug donanemab two years earlier could raise its modeled lifetime societal value per patient by 32%, from $104,900 to $138,300. The study, published Oct. 7 in Alzheimer’s & Dementia, estimates health and economic benefits; it does not subtract the costs of the drug or the screening and monitoring needed to provide treatment.
The team used a dynamic microsimulation model to project outcomes across patients’ lifetimes. It compared people receiving donanemab at a timing resembling participants in a pivotal Phase 3 trial with a modeled group starting treatment two years sooner, after symptoms typically emerge, and a group receiving no treatment. The model assumed a 29% slowing of disease progression for treated groups, matching the trial’s reported comparison with placebo after 18 months.
Compared with no treatment, the trial-timing scenario projected about 0.3 additional years of life, one fewer year living with severe dementia, 0.37 more disability-free years and 0.63 more years living in the community. The researchers assigned this outcome a lifetime societal value of $104,900 per person. They attributed $52,300 to better health-related quality of life, $23,800 to reduced unpaid caregiving and $22,200 to medical cost offsets, largely accruing to Medicaid. The modeled annual Medicaid reduction was about $1,640, or 13%.
With treatment begun two years earlier, the estimated value rose to $138,300 per person. A separate scenario incorporating potentially stronger treatment effects suggested $179,400, 71% above the trial-timing estimate. The authors also tested a conservative case in which benefits lasted four years rather than a patient’s lifetime: the value was $49,100 at trial timing and $56,400 with earlier treatment. These are model outputs, not observed outcomes for a group of patients followed over their lifetimes.
Earlier Diagnosis Could Change Treatment Value
The findings put an economic estimate on the potential consequences of delays between symptoms, diagnosis and treatment. Alzheimer’s is diagnosed, on average, 3.5 years after symptoms begin, according to the study’s background. If a treatment works better when started earlier, identifying eligible patients sooner could affect time spent living independently, caregiving demands and public health spending.
The estimates may inform decisions about whether and how to expand access to treatment and diagnostic services. But the reported societal value is not the same as a cost-effectiveness finding or a calculation of net savings: the model excludes the drug price and the costs of finding, screening and monitoring patients. Those expenses would need to be weighed against projected benefits before the figures could guide a coverage or budget decision.
The researchers also modeled hypothetical future drugs. A treatment that slows progression by 50% was assigned a lifetime social value of $208,700 to $276,700, depending on when it begins; a hypothetical treatment that halts progression was valued at $530,000 to $648,300. These scenarios are projections, not evidence that such treatments are available or will produce those outcomes.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Oral-B iO Series 9 Limited Rechargeable Electric Toothbrush with 7 Cleaning Modes
Garmin Venu 3 Fitness Smartwatch, 45 mm, Black
As an affiliate, we earn on qualifying purchases.
How the Treatment Scenarios Were Built
The study draws on the USC Schaeffer Center’s U.S. Cost of Dementia Project, a federally funded effort to quantify dementia’s costs. Researchers used national health surveys and studies of dementia progression to model patients’ lifetime cognitive status with a commonly used scoring measure. Their modeled group was designed to resemble participants in a pivotal donanemab trial.
Donanemab, marketed as Kisunla, targets amyloid plaque buildup in the brain. The study says use of this class of treatment has been limited by coverage restrictions, costs and the practical challenges of identifying and monitoring eligible patients. It also points to FDA-approved blood-based biomarker tests in the past year and newer digital cognitive assessments as tools that may help identify disease earlier; the study does not establish how widely these tools are used or how much they would reduce diagnostic delays.
The financial context is substantial: the source report estimates that Alzheimer’s and related dementias will cost the United States $818 billion in 2026, with the economic impact expected to grow as the population ages. That figure describes the broader burden of dementia, not costs that the modeled donanemab use would necessarily avert.
“Our research suggests that investments in early detection could help ensure that patients start treatments when they’re more likely to provide the greatest benefit to patients and society.”
— Jack Chapel, lead author, USC Schaeffer scholar and assistant research professor at the USC Price School of Public Policy
Costs and Benefit Duration Remain Uncertain
The model’s conclusions depend on how much donanemab slows disease progression and how long that effect continues. Because these therapies are new, the researchers said the duration of benefit is uncertain. Their four-year scenario substantially reduced estimated value compared with assuming benefits persist for the rest of a patient’s life, although it still projected a higher value with earlier treatment.
The analysis does not include the costs of the drug or the screening and monitoring required to deliver it. It therefore does not establish whether earlier treatment would save money overall, how many patients could be identified and treated, or what access would cost health systems. Nor does it show that starting treatment two years earlier produces the modeled gains in real-world patients. The source material does not provide a confidence interval or a direct clinical comparison of the two treatment start times.
Further Evidence Will Shape Access Decisions
The study’s estimates may contribute to future discussions about early diagnosis, treatment access and the resources needed to support screening and monitoring. The source report does not identify a specific policy decision or follow-up analysis with a scheduled date. Clinical evidence on how long benefits last, alongside real-world evidence on outcomes and delivery costs, will be needed to test the assumptions behind the projections.
The researchers also point to a pipeline of more than 150 Alzheimer’s drugs undergoing clinical testing, though that figure does not mean those candidates will prove effective or reach patients. As new treatments and diagnostic tools are studied, updated models could compare their benefits with their full delivery costs and assess how results vary by treatment timing.
Key Questions
What did the study estimate about starting donanemab earlier?
The model estimated $138,300 in lifetime societal value per person when treatment began two years earlier, compared with $104,900 at a timing resembling the clinical trial. The higher estimate is a projection, not an observed result from a long-term patient comparison.
What does “societal value” include in this analysis?
The estimate combines modeled health-related quality-of-life gains, reduced unpaid caregiving and medical cost offsets. In the trial-timing scenario, the largest component was $52,300 for health-related quality of life, followed by $23,800 for unpaid care and $22,200 in medical cost offsets.
Did the researchers include the price of donanemab?
No. The estimates exclude the drug’s cost as well as expenses for screening and monitoring. The study therefore does not show whether treatment would produce net savings after those costs are counted.
How certain are the projected benefits?
They depend partly on how long treatment effects last. In a modeled scenario where benefits lasted four years rather than a patient’s lifetime, estimated value fell to $49,100 at trial timing and $56,400 with earlier treatment. The authors say the duration of benefit remains uncertain.
Source: rss
